Cellevate AB

10/03/2026

🚀 Exciting news from Cellevate!

We’re proud to announce a new strategic collaboration with U.S.-based InVitria.

This partnership represents an important step in validating Cellevate’s technology within an integrated upstream workflow alongside a recognized U.S. media provider. By combining our Cellevat3d® advanced nanofiber-based cell culture workflows with chemically defined media, the companies aim to deliver improved viral titers, enhanced scalability, reduced resource consumption, and significantly improved productivity at lower costs — key drivers for industrial vaccine production.

Read more in the press release: https://cellevate.com/cellevate-ab-and-invitria-inc-enter-strategic-collaboration-to-advance-upstream-bioprocessing-solutions-for-viral-vaccine-production/

22/12/2025

🌟 Thank you to everyone who has been part of Cellevate’s journey in 2025. We truly appreciate your trust and collaboration and look forward to continuing our work together in 2026.

Wishing you a joyful holiday season and a Happy New Year! ✨ — The Cellevate Team

16/12/2025

🎉Cellevate has achieved ISO 9001:2015 certification and implemented GMP production processes in new cleanroom, marking a major milestone for Cellevate to becoming an industrial bioprocessing supplier!

The certification reflects Cellevate’s dedication to delivering the highest standard of quality assurance throughout all its processes, from the business plan and company management to research and development, production, sales and marketing, product delivery and customer support.

The implementation of GMP processes for production in the new cleanroom enables controlled, robust and scalable manufacturing of our Cellevat3d® nanofiber products, supporting increasing demand from global partners, CDMOs, and biopharmaceutical companies.

👉 Read the full press release here: https://cellevate.com/cellevate-caps-strong-2025-by-achieving-iso-90012015-certification-and-implementing-gmp-production-processes-in-new-cleanroom/

28/10/2025

Excited to see our CEO Laura Chirica featured in The Pharma Navigator!
In this interview, she shares how our Cellevat3d® nanofiber microcarriers are transforming vaccine manufacturing and unlocking new much needed potential for the industry.

🎥 Watch the full interview here and let’s connect at CPHI Frankfurt to continue the conversation!
https://www.thepharmanavigator.com/news/cphi-frankfurt-2025-unlocking-the-potential-of-3d-cell-cultures-in-vaccine-production-with-novel-nanofiber-platform

Implementation of three-dimensional (3D) cell culture nanofiber systems in industrial vaccine production offers much higher viral vaccine titers, greater scalability and improved process economy, but it will require tight collaboration with the industry to help speed up their wide adoption, stresses

13/10/2025

📢 Cellevate announces major advances in yield and scalability of viral vaccine production with global launch of Cellevat3d® VAX nanofiber microcarriers

Read our latest press release for more information 👉 https://cellevate.com/cellevate-to-announce-major-advances-in-yield-and-scalability-of-viral-vaccine-production-at-world-vaccine-congress-europe-with-global-launch-of-cellevat3d-vax-nanofiber-microcarriers/

Key highlights:
✅ >13-fold higher infectious viral vaccine titers in Vero cell cultures compared to industry-standard microcarriers
✅ 11.4-fold higher infectious enterovirus vaccine titers demonstrated in HEK293T cultures in an independent study conducted by Intravacc B.V. (CDMO, The Netherlands)
✅ Formation of homogeneous, high-density 3D spheroid cultures, supporting efficient virus propagation, high cell-specific viral productivity and scale-up
✅ 85% reduction in cost of production for viral vaccine processes compared to current industry-standard

“With this new product launch, Cellevate demonstrates the versatility of its next-generation, nanofiber-based microcarrier platform across all areas of adherent cell cultivation. Breakthrough medicine requires breakthrough innovations in biomanufacturing and Cellevate will keep delivering on that paradigm.”
— Dr. Uwe Gottschalk, Chairman of the Board, Cellevate

10/10/2025

🚀Cellevate launches new nanofiber product for vaccine production next week!

Cellevat3d® VAX nanofiber microcarriers provide more than 10-fold increase in viral vaccine titers. See you at World Vaccine Congress Europe in Amsterdam, Oct 14–16! ✨

Launch presentation: Manufacturing Technologies Track, October 16, at 12.30 presented by Dr. Christel Fenge, CTO Cellevate.

📍 Connect with us on site, Laura Chirica, PhD, CEO and Dr. Christel Fenge, CTO

17/09/2025

✨Cellevate at CPHI in Frankfurt, October 28–30!
Laura Chirica, PhD (CEO) and Bettina Berendsen (Strategic Advisor & Board Member) will be on-site at CPHI to simply meet and discuss how Cellevat3d® nanofibers can help to eliminate cell culture bottlenecks in biomanufacturing. Let’s talk about Cellevat3d® VAX nanofibers for vaccine production!

🌟 Key benefits:
✅ Up to 14-fold higher yields vs. current processes
✅ Easy scale-up
✅ Faster bioprocessing and enhanced productivity
✅ High quality
✅ Reduced waste and water use
✅ Improved production economy

🚀 Don’t miss the global launch of Cellevat3d® VAX nanofiber microcarriers at the World Vaccine Congress Europe in Amsterdam, October 14-16, 2025.

📍 Let’s connect at CPHI - reach out to schedule a meeting!

19/08/2025

🚀 More than 10-fold increase in viral vaccine production titers with Cellevat3d® nanofiber microcarriers!

Today, we are excited to share results from Cellevate’s vaccine production validation program dedicated to evaluating cell culture products based on our proprietary nanotechnology Cellevat3d®.

🔬 Key highlights:
• Dense and uniform 3D spheroid formation with Vero cells
• High infectious titers of enterovirus A71 (EV71) successfully produced in nanofiber-based cultures
• Independent benchmarking by Intravacc (CDMO, NL) showed:
✨ 11.4-fold increase in infectious virus titers
✨ 17-fold improvement in cell-specific virus yield

These results underline the ability of Cellevat3d® to dramatically enhance vaccine manufacturing, with the potential of cutting production costs by up to 85% while boosting scalability and sustainability.

The Cellevat3d® VAX nanofiber microcarriers will be launched at World Vaccine Congress Europe in Amsterdam, October 13-16 2025.

📄 A full summary of the performance data is available in our new Application Note.

👉 Read more in our press release and download the Application Note.
https://cellevate.com/more-than-10-fold-enhanced-viral-vaccine-production-titers-using-the-novel-cellevat3d-nanofiber-microcarriers/

04/06/2025

💬 “What excites you most about Cellevate’s journey, and where do you see the company heading?
There are three things that truly excite me. First, our Cellevat3d® nanofiber microcarriers can reduce the cost of viral vector therapy production by up to 70% – a game-changer, considering current treatments can cost up to €1 million per dose. This has the potential to dramatically improve access to life-saving therapies for millions of patients. Second, I’m incredibly proud that we brought our first product to market in under three years – a remarkable team achievement for any biotech company. Lastly, I’m energised by our strategic partnerships with leading pharma companies, CDMOs, and bioprocessing providers. Together, we’re working towards more sustainable, scalable solutions that can reduce costs, improve yields, and ultimately support better, more accessible healthcare.”

In the Life Science Barometer 2025 – Skåne Edition, our CEO Laura Chirica, PhD shares insights on Cellevate’s journey, the challenges of commercialization, and what it takes for life science startups to scale and succeed globally.

📖 Read the full interview in the Life Science Barometer 2025 – Skåne Edition report by Medicon Village (p.23):
https://www.mediconvillage.se/app/uploads/2025/05/Medicon-Village-Life-Science-Barometer-Skane-2025-final-report.pdf

The report, focused mainly on the Southern part of Sweden, Skåne, provides a snapshot of the life science industry outlining the current economic challenges, geopolitical tensions, funding, creating value, patenting, HR outlook and investor perspectives on the current investment climate and how to be successful.

02/06/2025

✨Meet Cellevate at New Horizons in Biologics & Bioprocessing in Copenhagen on June 3!

Our Sales & Marketing Director, Nils Uhlin, will be on-site connecting, partnering and eager to discuss about the upstream bioprocessing needs for increased yield, scalability and decreased cost of production and how Cellevat3d® nanofiber products address these challenges.

📍Looking forward to seeing you in Copenhagen!

15/05/2025

📅 Day 2 of ASGCT in New Orleans ends with our North American Applications Manager, Geddy Hamblen, presenting our Cellevat3d® technology for increasing viral vector production.

📍Stop by our booth #952 Thursday or Friday to learn more about how Cellevate can support your cell and gene therapy manufacturing process.

15/05/2025

📍 Live from BPI Europe in Hamburg!
Great discussions and valuable exchanges this week around our innovative Cellevat3d® nanofiber technology at BioProcess International Europe.

📸 Here’s a snapshot of Dr. Christel Fenge, our CTO, at yesterday’s poster presentation, where we highlighted how our nanofiber-based cell culture systems are driving yield and productivity in upstream viral vector bioprocessing.

Thanks to everyone who stopped by and engaged in thoughtful conversations! 🙏